SCHEMBL2342500

SCHEMBL2342500

N#Cc1ccc(N2CC[CH]CC2)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.39
LCAT P04180 1/20 0.38
PARP1 P09874 2/20 0.37
TNK2 Q07912 2/20 0.37
TNK1 Q13470 2/20 0.37
AR P10275 1/20 0.37
CHRNB2 P17787 2/20 0.37
CHRNA4 P43681 2/20 0.37
CHEK1 O14757 3/20 0.36
PDE4B Q07343 1/20 0.36
PDE4D Q08499 1/20 0.36
ACHE P22303 1/20 0.36
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
MEN1 O00255 1/20 0.35
KCNJ1 P48048 1/20 0.35
KCNH2 Q12809 1/20 0.35
OPRM1 P35372 1/20 0.34
OPRL1 P41146 1/20 0.34
MAPT P10636 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27909230 0.86 CHRNB2 (0.44) AOC3LCATPARP1TNK2TNK1
SCHEMBL151047 0.86 MAPT (0.46) AOC3LCATPARP1TNK2TNK1
SCHEMBL148390 0.84 MAPT (0.49) AOC3LCATPARP1TNK2TNK1
SCHEMBL151160 0.84 MAPT (0.49) AOC3LCATPARP1TNK2TNK1
SCHEMBL718760 0.81 CHRNB2 (0.58) CHRNB2CHRNA4CHEK1
SCHEMBL151032 0.81 CHEK1 (0.51) AOC3CHEK1ACHEKDM4EMEN1
SCHEMBL153260 0.81 CHEK1 (0.52) CHEK1KDM4ETP53MEN1MAPT
SCHEMBL29612110 0.81 CHEK1 (0.51) AOC3CHEK1ACHEKDM4EMEN1
Hydrochloric Acid SCHEMBL23303948 0.80 CHRNB2 (0.57) CHRNB2CHRNA4CHEK1
SCHEMBL20644559 0.80 CHRNB2 (0.41) AOC3LCATPARP1TNK2TNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-09-22 US claimed
EP-2361902-A1 4,6-DIAMINONICOTINAMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-08-31 EP claimed
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
EP-2361902-A1 4,6-DIAMINONICOTINAMIDE COMPOUND Astellas Pharma Inc. (JP) 2011-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230467-A1 4,6-DIAMINONICOTINAMIDE COMPOUND JAK3, JAK2, JAK1 AOC3 560/4885LCAT 3947/4885PARP1 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.